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Background: DNA methylation is an epigenetic modification that plays an important role during mammalian
development. Around birth in humans, the main site of red blood cell production moves from the fetal liver to the
bone marrow. DNA methylation changes at the β-globin locus and a switch from fetal to adult hemoglobin
production characterize this transition. Understanding this globin switch may improve the treatment of patients
with sickle cell disease and β-thalassemia, two of the most common Mendelian diseases in the world. The goal of
our study was to describe and compare the genome-wide patterns of DNA methylation in fetal and adult human
erythroblasts.
Methods: We used the Illumina HumanMethylation 450 k BeadChip to measure DNA methylation at 402,819 CpGs
in ex vivo-differentiated erythroblasts from 12 fetal liver and 12 bone marrow CD34+ donors.
Results: We identified 5,937 differentially methylated CpGs that overlap with erythroid enhancers and binding sites
for erythropoiesis-related transcription factors. Combining this information with genome-wide association study
results, we show that erythroid enhancers define particularly promising genomic regions to identify new genetic
variants associated with fetal hemoglobin (HbF) levels in humans. Many differentially methylated CpGs are located
near genes with unanticipated roles in red blood cell differentiation and proliferation. For some of these new
candidate genes, we confirm the correlation between DNA methylation and gene expression levels in red blood
cell progenitors. We also provide evidence that DNA methylation and genetic variation at the β-globin locus
independently control globin gene expression in adult erythroblasts.
Conclusions: Our DNA methylome maps confirm the widespread dynamic changes in DNA methylation that
occur during human erythropoiesis. These changes tend to happen near erythroid enhancers, further highlighting
their importance in erythroid regulation and HbF production. Finally, DNA methylation may act independently of
the transcription factor BCL11A to repress fetal hemoglobin production. This provides cues on strategies to more
efficiently re-activate HbF production in sickle cell disease and β-thalassemia patients.Background
DNA methylation is a dynamic epigenetic mark mostly
found on cytosine residues of certain CpG dinucleotides
in mammalian genomes. In humans, it is involved in gene
imprinting, X-chromosome inactivation, and transposable
element suppression [1]. DNA methylation is generally
associated with transcriptional silencing and plays an
essential role in maintaining stem cell pluripotency and* Correspondence: guillaume.lettre@umontreal.ca
1Montreal Heart Institute, 5000 Bélanger Street, Montréal, Québec H1T 1C8,
Canada
2Faculté de Médecine, Université de Montréal, 2900 Boul. Édouard-Montpetit,
Montréal, Québec H3T 1J4, Canada
Full list of author information is available at the end of the article
© 2015 Lessard et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.controlling other cell- or organ-specific developmental
programs [1]. Despite the well-established role of DNA
methylation during development, we are only now starting
to collect single-base resolution maps of these develop-
mentally regulated DNA methylation changes thanks to
improvements in DNA array- and sequencing-based
technologies [2]. Such precise DNA methylome maps
are important in order to understand how transcrip-
tional networks are controlled during development or
how dys-regulation of DNA methylation - observed in
human diseases like cancer or upon treatment with
DNA demethylating agents - may impact cell func-
tions and/or identity [3].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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letions of genes that encode DNA methyltransferases -
enzymes that catalyze the transfer of methyl groups onto
DNA - has firmly established that DNA methylation is
essential during hematopoietic stem cell differentiation
and repopulation [4,5]. Recent reports used enrichment
of methylated DNA followed by next-generation DNA
sequencing to characterize genome-wide DNA methy-
lation changes in murine hematopoietic stem and
progenitor cells, and during erythropoiesis [6,7]. The
studies showed a progressive DNA demethylation
during erythroid differentiation, and confirmed that
groups of CpGs in promoters - so-called CpG islands -
tend to be hypomethylated and correlated with active
gene expression [6,7].
Although large-scale projects are starting to generate
comprehensive DNA methylation datasets [8], they do
not capture all stages of human erythroid differentiation
and proliferation. In an initial study, investigators moni-
tored genome-wide changes in DNA methylation during
human erythropoiesis of bone marrow-derived CD34+
progenitor cells and reported global DNA hypomethyla-
tion [9]. We are particularly interested in the epigenetic
differences between fetal- and adult-stage erythroblasts
that originate, respectively, from the fetal liver and the
bone marrow. The large epigenomic projects (e.g. EN-
CODE, Roadmap Epigenomic, Blueprint) do not profile
DNA methylation in these erythroid cells. During this
erythroid transition, which occurs around birth in humans,
erythroblasts reduce the production of fetal hemoglobin
(HbF) and increase the production of adult hemoglobin
(HbA) through the transcriptionally regulated fetal-to-adult
hemoglobin switch [10]. This gene expression switch is
accompanied by progressive DNA hypermethylation of the
HBG2 promoter, which encodes the γ-globin subunit of
HbF [11,12]. Understanding the molecular mechanism be-
hind the fetal-to-adult hemoglobin switch is particularly
important since re-activating HbF production is the most
promising therapy for patients with sickle cell disease and
β-thalassemia [10]. Ex vivo differentiation protocols now
exist to cultivate sufficient number of fetal and adult human
erythroblasts to extend the characterization of DNA methy-
lation to the rest of the genome [13].
Here we provide comprehensive DNA methylome
maps of human erythroblasts differentiated ex vivo from
CD34+ progenitor cells purified from the fetal liver or
the bone marrow. By analyzing DNA methylation values
at 402,819 tested CpGs in fetal and adult erythroblasts,
we identified 5,937 differentially methylated CpGs.
These differentially methylated regions include the
known β-globin locus, other genes with known roles in
erythropoiesis, as well as several other genes with no
previously recognized functions in red blood cell differen-
tiation. We showed that the differentially methylatedCpGs cluster within stage-specific erythroid enhancers
and are located near binding motifs for transcription fac-
tors that regulate hematopoiesis. Finally, we determined
that DNA methylation and genetic variation at the β-glo-
bin locus independently control HbF production in adult-
stage cells.
Methods
Cell culture and differentiation
Primary human fetal and adult CD34+ hematopoietic
stem/progenitor cells harvested from 24 anonymous do-
nors (12 of each) were purchased from DV Biologics
[14] and Lonza [15], respectively. Primary fetal and adult
erythroblasts were generated using two-phase serum-
free culture as described previously [13]. Briefly, primary
human fetal and adult CD34+ cells are cultured in the
expansion medium until day 6. They are then transferred
to the differentiation medium until cells are collected
at day 18. The medium is changed every 3 days. We
assessed cell morphology by Wright-Giemsa coloration,
and measure cell size and count using the MOXI Z Mini
automated cell counter (ORFLO technologies, ID), and
hemoglobin production by capillary electrophoresis.
Genomic DNA extraction and methylation assay
We extracted genomic DNA with the Gentra Puregene
Cell Kit (Qiagen). DNA was further precipitated with
alcohol in order to obtain highly purified DNA. DNA
bisulfite conversion was performed using the EZ DNA
Methylation Gold Kit (Zymo Research, CA, USA). We
used the Infinium HumanMethylation450 BeadChip
(Illumina Inc., CA, USA) to measure genome-wide pat-
terns of DNA methylation; the experiment was carried
out at the Genome Quebec-McGill Innovation Centre
using Illumina’s recommended protocol. We assessed
data quality with the minfi R package [16] and normal-
ized intensities using the ARRm software, which corrects
for probe type, background, dye, and position effects
[17]. We removed probes that target a genomic se-
quence annotated to carry genetic variants based on
dbSNP version 137 (N = 82,694). DNA methylation data
have been submitted and are available from the National
Center for Biotechnology Information (NCBI) Gene Ex-
pression Omnibus (GEO) repository (accession number
(GEO: GSE56491)). To identify single CpG that are
differentially methylated between fetal and adult erythro-
blasts, we converted DNA methylation β-values into M-
values [18] and used linear regression in R, correcting
for sex effects. To combine results across CpGs located
within a functional genomic unit, we used a generalization
of Fisher’s method that takes into account correlation be-
tween nearby CpGs and that is already implemented in
the RnBeads software [19]. We used RefSeq (release 61)
coordinates to map CpGs to specific genes. Promoter
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and enhancer CpGs map to erythroid enhancers ex-
perimentally identified in ex vivo differentiated CD34+
cells [20]. In total, we could map 233,894 CpGs to
25,891 gene bodies, 130,854 CpGs to 25,103 promoters,
and 11,709 CpGs to 4,604 erythroid enhancers. DNA
methylation levels at the HBG2 promoter were measured
using the MassArray EpiTYPER platform (Sequenom Inc.,
CA, USA), which quantitatively analyze fragmented PCR
products using MALDI-TOF mass spectrometry. Bisulfite-
converted DNA was amplified by PCR as previously de-
scribed [21].
RNA extraction and gene expression analysis
RNA was extracted using the RNeasy Plus Mini Kit from
Qiagen. We determined the quality and quantity of RNA
using the RNA 6000 Nano kit on the Bioanalyzer instru-
ment (Agilent). We converted RNA into cDNA with the
High Capacity cDNA Reverse Transcription Kit (ABI)
and performed quantitative PCR using the Platinum
SYBR Green qPCR Mix (Invitrogen). Relative gene ex-
pression levels were measured using the ΔΔCt method
and we evaluated statistical significance with t-test as
implemented in the R software (v. 3.0.0). Primer se-
quences are listed in Additional file 1: Table S1. Total
RNA for RNA sequencing was extracted using the miR-
NEASY kit (Qiagen). Paired-end RNA sequencing was
performed on the Illumina Hiseq 2000 platform. Reads
were mapped to the genome using Tophat2 (v.2.0.9) and
transcript abundances were estimated using Cufflinks
(v.2.2.1).
Enrichment analyses
We used binomial tests to measure the enrichment of
differentially methylated CpGs in gene bodies, pro-
moters, and erythroid enhancers as compared to the
rest of the genome surveyed by the Illumina Human-
Methylation450 BeadChip. To compare the enrichment
of differentially methylated CpGs in erythroid en-
hancers versus other enhancers present in different cell
types, we obtained enhancer coordinates from nine cell
lines analyzed by the ENCODE Project [22]. We used
DAVID to measure the enrichment of gene ontology
(GO) terms and biological pathways among genes with
a mean β-value difference >0.1 and a combined P <9 ×
10−7 in their body or promoter, taking into account the
coverage of the Illumina HumanMethylation450 Bead-
Chip [23,24]. To identify transcription factor binding
motifs that are enriched at differentially methylated
loci, we used the HOMER software and a list of 495
pre-defined transcription factor motifs [25], limiting the
search to 200 base pairs on both sides of differentially
methylated CpGs. For this analysis, we compared the 5,000
most hypomethylated regions in fetal erythroblasts to the5,000 most hypomethylated regions in adult erythroblasts,
as recommended. HOMER results were stable using differ-
ent thresholds to select hypomethylated regions.
DNA genotyping and association studies
Genotyping was performed at the Pharmacogenomics
Center of the Montreal Heart Institute using the
HumanOmniExpress BeadChip array (Illumina). We
performed quality-control steps with PLINK [26], remov-
ing markers with genotyping success <90% or Hardy-
Weinberg P <1.0 × 10−6. All samples had a genotyping
success rate >99.8%. We imputed genetic variants with the
MaCH/minimac software [27] and reference haplotypes
from the 1000 Genomes Project (phase I). For association
analysis, we only considered genotyped markers or
markers with an imputation quality r2_hat >0.6. We
tested association between SNP genotypes and methy-
lation levels under an additive model using linear regres-
sion as implemented in R. For BCL11A, we tested CpGs
inside the gene body or the promoter (chr2:60,678,302-
60,781,633). For HBS1L-MYB, tested CpGs were either
inside the gene bodies and promoters of the genes, or
in the intergenic region (chr6:135,281,517-135,540,311).
For the β-globin locus, all CpGs between the promoter
of HBE and the gene body of HBB were included
(chr11:5,246,696- 5,527,882).
To test the enrichment of HbF association signals with
DNA methylation-implicated erythroid enhancers, we
accessed genome-wide association study (GWAS) data
of 1,140 African Americans from the Cooperative Study
of Sickle Cell Disease (CSSCD). These individuals were
genotyped on the Illumina Human610-Quad array, as
previously described [28]. SNPs were phased using
MaCH (v1.0.16) and imputed with haplotypes from
European and African samples generated by the 1000
Genomes Project (phase I) using minimac (v4.4.3). Associ-
ation P values with HbF were calculated using mach2qtl
(v1.0.8). In total, 6,994,357 SNPs were included in the ana-
lysis. We found 63,876 SNPs that overlap with 12,683
erythroid enhancers.
Results and discussion
Ex vivo culture of erythroid progenitor cells
We used a previously established two-phase cell culture
protocol to expand and differentiate primary human
fetal and adult CD34+ hematopoietic stem/progenitor
cells into erythroblasts [13]. For each tissue (fetal liver
or bone marrow), we differentiated CD34+ cells from 12
anonymous donors to compare not only DNA methyla-
tion changes between fetal and adult erythroblasts, but
also between individuals within a developmental stage.
We validated the expansion and differentiation cell cul-
ture protocol by characterizing cell size, growth, and
morphology (Additional file 1: Figure S1). To determine
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istics that are specific to their tissue of origin, we mea-
sured expression of genes involved in the fetal-to-adult
hemoglobin switch and quantified hemoglobin produc-
tion by capillary electrophoresis. As expected, erythro-
blasts derived from bone marrow express significantly
more BCL11A and KLF1 than fetal erythroblasts
(Additional file 1: Figure S2A-B). BCL11A and KLF1
are transcriptional repressors of HBG2 gene expres-
sion; KLF1 also increases HBB gene expression, which
encodes the β-globin subunit of HbA [13,29-31]. Con-
sistently, erythroblasts from the fetal stage produce
exclusively HbF (100 ± 0%) whereas differentiated cells
from the adult stage produce mostly HbA (84.2 ±
4.8%) (Additional file 1: Figure S2C-E). Using a tar-
geted assay that measures DNA methylation at seven
CpGs within the HBG2 promoter, we also confirmed
hyper- and hypomethylation of this promoter in adult
and fetal erythroblasts, respectively (Additional file 1:
Figure S3) [32]. Taken together, these results confirm
that the erythroblasts have maintained their develop-
mental stage specificity.
In the mouse and humans, it is known that global de-
methylation occurs during erythropoiesis [6,7,9]. For this
reason, it is important to confirm that fetal and adult
erythroblasts grow and differentiate under similar kinet-
ics. To directly address this concern, we performed a
time-course analysis of the expression of genes that code
for markers of differentiation and that are localized at
the cell surface of erythroblasts: CD34, CD71 (transferrin
receptor (TRFC)), and CD235a (glycophorin A (GYPA)).
Recent transcriptomic analyses in ex vivo-differentiated
human erythroblasts have confirmed that the expression
levels of these genes are strongly correlated with the
localization of the encoded proteins at the cellular mem-
brane [33,34]. As expected, CD34 is highly expressed at
the beginning of differentiation and decreases thereafter,
whereas the expression of CD71 and CD235a increases
during differentiation (Additional file 1: Figure S4). At
any given time point, the expression of these three genes
was not different between fetal liver- and bone marrow-
derived CD34+ progenitors cells, except for CD235a at
the beginning of differentiation (more expressed in fetal
liver cells) (Additional file 1: Figure S4). These results
confirm that fetal and adult erythroblasts grow and
differentiate at a similar rate, and therefore that our
experiment is adequate to detect differences in DNA
methylation that are mostly due to the different develop-
mental stage (fetal liver vs. bone marrow) of these cells.
The DNA methylation landscape in human erythroblasts
We used the Illumina HumanMethylation 450 k Bead-
Chip to measure quantitatively DNA methylation across
the genome in ex vivo-differentiated erythroblasts from12 fetal liver and 12 bone marrow donors. After quality
control and intensity normalization steps, we obtained
DNA methylation β-values (from 0.0 (unmethylated) to
1.0 (fully methylated)) for 402,819 CpGs (Additional file
1: Figure S5). We only used these CpGs in subsequent
analyses. We used DNA methylation data generated by
the Roadmap Epigenomics Project [35] using reduced
representation bisulfite DNA sequencing (RRBS) from
mobilized adult CD34+ cells to validate the DNA methy-
lation levels measured in erythroblasts with the Illumina
HumanMethylation 450 k BeadChip. Although not dif-
ferentiated ex vivo, we reasoned that these CD34+ cells
would be a good proxy for adult erythroblasts used in
our experiment. Across 80,136 CpGs available in both
datasets, we observed a strong correlation of DNA
methylation values (Pearson’s r = 0.91, P <2.2 × 10−16,
Additional file 1: Figure S6A). Importantly, we repeated
the same analysis with other RRBS datasets from the
Roadmap Epigenomics Project. We observed that DNA
methylation values in erythroblasts are more correlated
with DNA methylation data from blood-related rather
than blood-unrelated cells or tissues (Additional file 1:
Figure S6B). These comparisons confirm the quality and
specificity of the DNA methylation data generated with
the Illumina 450 k array in human erythroblasts.
We analyzed DNA methylation across all CpGs tested
using unsupervised clustering methods. The two main
clusters accurately distinguish fetal liver- from bone
marrow-derived erythroblasts (Figure 1). This result
confirms our hypothesis that changes in DNA methyla-
tion captures developmental differences between fetal
and adult erythroblasts. We also noted that the two
main stage-specific clusters are sub-divided according to
the sex of the sample’s donors (Figure 1). This sex-
specific clustering is mostly dependent on DNA methy-
lation values at CpGs located on the X-chromosome.
Differential DNA methylation between fetal and adult
erythroblasts
We sought to identify differentially methylated single
CpG sites by comparing methylation β-values for fetal
and adult erythroblasts, taking into account potential
sex effect. We used two criteria to define differentially
methylated CpGs: a difference in β-values of ≥0.2 and a
P ≤1.25 × 10−7 (significant threshold after Bonferonni
correction). Using this definition, we found 5,937 differ-
entially methylated CpGs (Figure 2A and Additional file
2: Table S2).
We discuss below two interesting examples of differ-
entially methylated loci detected in human erythroblasts.
GCNT2 encodes the enzymes responsible for the con-
version of the blood i- to the I-antigen during the fetal-
to-adult transition in erythroblasts. GCNT2 codes for
three isoforms: isoform C is responsible for the I-antigen
Figure 1 Hierarchical clustering analysis of DNA methylation in erythroblasts. Unsupervised clustering analysis of DNA methylation at
402,819 CpGs separates precisely fetal liver-derived from bone marrow-derived erythroblasts. Within each developmental stage, cells are
sub-divided by the sex of the donors. The top panel represents the dendogram of the different clusters identified. The middle panel sum-
marizes pairwise correlations between all samples. In the bottom panel, black rectangles identify male and female donors. BM: adult eryth-
roblasts; FL: fetal erythroblasts.
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system, we found that cg14322298 in the promoter of
isoform C is hypomethylated in adult erythroblasts (Δβa-
dult-fetal = −0.47, P = 8.0 × 10
−16; Figure 3A). We found
that GCNT2-C expression levels correlate with DNA
methylation at cg14322298 in erythroblasts (Figure 3B).
Isoform B had very low expression in both fetal and
adult erythroblasts, whereas isoform A and C explained
most of GCNT2 expression in fetal (72.2%) and adult
(75.1%) erythroblasts, respectively (Additional file 1:
Figure S7). Another example of differentially methylated
loci include CpGs in the ARID3A/Bright gene that
show a marked differential DNA methylation pattern,
being almost completely methylated in fetal-stage cells(e.g. cg08894487, Δβadult-fetal = −0.93, P = 3.8 × 10
−21)
(Figure 3C). This gene is required for hematopoietic
stem cell development: definitive erythrocyte formation in
the fetal liver is impaired in Bright knockout mice, but not
at the primitive (embryonic) stage [37]. ARID3A expres-
sion was higher in fetal erythroblasts (Figure 3D). Positive
correlations between DNA methylation inside gene bodies
and gene expression levels have been reported previously
[38]. Overall, we observed a global enrichment of positive
correlations between DNA methylation at CpGs inside
gene bodies and expression levels in erythroblasts. In con-
trast, there is a marked enrichment of negative correla-
tions between CpGs within promoters or enhancers, and
gene expression (Additional file 1: Figure S8).
Figure 2 Differential DNA methylation between fetal liver- and bone marrow-derived erythroblasts. Volcano plots of differentially
methylated (A) CpGs, (B) genes, (C) promoters, and (D) erythroid enhancers. Differentially methylated single CpGs have a difference in DNA
methylation β-values between fetal and adult erythroid cells ≥20% and a P ≤1.25 × 10−7. Red and blue points correspond to CpGs significantly
hypomethylated in fetal- and adult-stage erythroblasts, respectively. For genes, promoters, and erythroid enhancers, we combined P values from
CpG sites that fall within each unit using a generalization of Fisher’s method to take into account correlation of values at nearby sites. For genes,
promoters, and enhancers, we averaged the DNA methylation β-values of the CpGs that fall within the unit (y-axis). We used a Bonferonni-adjusted
statistical threshold to define differentially methylated functional regions. (E) An enrichment of differentially methylated CpGs was observed in erythroid
enhancers when compared to gene or promoter regions also tested on the Illumina HumanMethylation 450 k BeadChip. We used probes that fall
outside of these regions to calculate the fold enrichment. (F) Erythroid enhancers (red) are enriched in differentially methylated CpGs when compared
to enhancers defined in other cell lines using data from the ENCODE Project.
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methylated CpGs
To link changes in DNA methylation to biologically rele-
vant functional units, we combined results from single
CpGs that fall within each of 25,891 transcripts defined
using RefSeq, 25,103 promoters (1.5-kb upstream of
RefSeq transcripts) and 4,604 erythroid enhancers [20].
These enhancers, defined using DNase I hypersensitive
sites and histone marks, include a set of enhancers that
is common to both fetal and adult erythroblasts, as well
as developmental lineage-specific enhancers [20]. After
Bonferonni correction (significance threshold set at
P <9 × 10−7), we found 77 genes, 116 promoters, and
303 erythroid enhancers that are differentially methyl-
ated (Figure 2B-D and Additional file 3: Table S3).
These analyses highlighted multiple regions of interest
(Additional file 3: Table S3). For instance, C22orf26 was
one of the most differentially methylated genes (meanΔβadult-fetal: −0.60; P = 6.2 × 10
−18). Although nothing is
known about this gene, it is located just upstream of the
microRNA let7-b host gene (MIRLET7BHG; Figure 3E).
The microRNA let-7b belongs to the let-7 family, is
highly expressed in adult as compared to fetal erythro-
blasts, and correlates with BCL11A expression and
reduced HbF levels [39]. It is possible that DNA methy-
lation at CpGs within or near C22orf26 regulates the ex-
pression of MIRLET7BHG. Notably, a nearby enhancer
active in adult-stage erythroblasts contain differentially
methylated CpGs, which correlates with MIRLET7BHG
expression (Figure 3F). Although the CpGs also corre-
lates with C22orf26 expression levels (Figure 3G), this
gene is an order of magnitude less expressed, and other
CpGs in its core promoter might also control its expres-
sion. Finally, we carried out a pathway-based analysis to
identify group of functionally related genes that are
differentially methylated. We found multiple pathways
Figure 3 Examples of loci differentially methylated between fetal- and adult stage erythroblasts. Each vertical line represents a targeted
CpG. Red and blue lines correspond to CpGs significantly hypomethylated in fetal- and adult-stage erythroblasts, respectively (P <1.25 × 10−7 and
Δβ ≥0.2). (A) A CpG in the promoter of GCNT2 isoform C, which is responsible for the conversion of the fetal i-antigen to the adult I-antigen, is
hypomethylated in adult-stage erythroblasts. (B) GCNT2-C expression levels is inversely correlated with DNA methylation at a CpG located in its
core promoter (r = −0.97, P = 4.6 × 10−14). (C) CpGs in an intron of ARID3A, a gene implicated in hematopoiesis, displays hypomethylation in
adult-stage erythroblasts. (D) DNA methylation inside ARID3A (highlighted) positively correlates with its expression levels (r = 0.87, P = 9.6 × 10−8).
(E) Differential DNA methylation near C22orf26 and the miRNA let7-b host gene (MIRLET7BHG). A cluster of hypomethylated CpGs in adult
erythroblasts overlaps an active erythroid enhancer (purple horizontal bars). DNA methylation inside the enhancer (highlighted) negatively
correlates with (F) MIRLET7BHG (r = −0.99, P = 5.6 × 10−20) and (G) C22orf26 expression levels (r = −0.74, P = 3.2 × 10−5).
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cytokine production, circulation, and cation transport
(Additional file 4: Table S4 and Additional file 1: Table
S5). Many of these pathways include genes not associ-
ated with erythropoiesis previously, and we need to val-
idate if differential DNA methylation translates into
biologically important functions.More generally, we asked whether there was an en-
richment of differentially methylated CpGs in genes,
promoters, and erythroid enhancers when compared
to the rest of the genome tested by the Illumina
HumanMethylation 450 k BeadChip. We observed a
strong statistically significant enrichment of differen-
tially methylated CpGs in erythroid enhancers (3.67-
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marginally significant in genes (1.03-fold, P = 0.04) and
we noted a significant depletion of differentially meth-
ylated CpGs in promoters (0.86-fold, P = 4.3 × 10−10)
(Figure 2E). The results for promoters and genes are
challenging to interpret given the ascertainment bias
in the design of the methylation array. However, this
technical confounding does not affect the result for
the erythroid enhancers since the release of the Illumina
HumanMethylation 450 k BeadChip pre-dated the publi-
cation of the erythroid enhancers [20]. Therefore, differen-
tial DNA methylation at erythroid enhancers likely
captures transcriptional and developmental differences be-
tween fetal and adult erythroblasts.
We then compared enrichment of differentially meth-
ylated CpGs in enhancers defined in nine different cell
types using data from the ENCODE Project [22]. Al-
though there was enrichment at enhancers from other
cell types - perhaps suggesting constitutive regulatory
functions - we observed the strongest enrichment for
erythroid enhancers defined in differentiated CD34+
cells (significant against enhancers from all other cell
types, P <4.5 × 10−17, Figure 2F) [20]. The enrichment of
differentially methylated CpGs within enhancers definedFigure 4 Erythroid enhancers are enriched for SNPs associated with f
Quantile-quantile (QQ) plot of association P values with HbF levels in 1,140
is shown in black (λGC = 1.01). In red are the 63,876 markers that map to er
after excluding enhancers near BCL11A, HBS1L-MYB and the β-globin locus (by ENCODE in erythroleukemic K562 cells was similar
to the enrichment observed in other, non-hematopoietic
cells (Figure 2F). This result may highlight a limitation
in using K562 cells to study the fine regulatory mecha-
nisms that control erythropoiesis.
Having demonstrated an enrichment of differentially
methylated CpGs in erythroid enhancers, we were inter-
ested in testing if these genomic regions are more likely
to contain genetic variants associated with HbF levels.
We analyzed associations between HbF levels measured
at baseline and genotypes at 6,994,357 markers in 1,140
adult patients with sickle cell disease [28]. As expected,
we observed a strong deviation from the null distribu-
tion owing to variants in the BCL11A, HBS1L-MYB, and
β-globin loci (Figure 4). When we considered only the
63,876 SNPs that overlap with erythroid enhancers, we
again observed deviation from the null expectation. This
departure from the null was even true - although more
modest - after excluding enhancers near the known HbF
regulators (Figure 4). This result directly implicates
erythroid enhancer in inter-individual HbF levels vari-
ation, and suggests that future genetic experiments to
find new HbF regulators should focus on these genomic
regions.etal hemoglobin (HbF) levels in patients with sickle cell disease.
sickle cell disease patients. The QQ plot for all 6,994,357 imputed SNPs
ythroid enhancers (λGC = 1.03) and in blue are the markers that remain
λGC = 1.02).
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preferentially located near differentially methylated CpGs
Data from the ENCODE Project support a passive role
for DNA methylation in controlling gene expression:
when a transcription factor is not or less expressed, the
CpGs surrounding its consensus binding sites tend to be
less accessible to DNase I digestion and to be more
methylated [40]. Based on this observation, we reasoned
that an analysis of transcription factor binding sites
within loci that are differentially methylated between
fetal and adult erythroblasts might yield new transcrip-
tion factors important for erythroid development. We
performed this analysis on the 5,000 most hypomethy-
lated CpGs in fetal erythroblasts and compared them to
the 5,000 most hypomethylated CpGs in adult erythro-
blasts. We obtained consistent results when using differ-
ent thresholds. We included 200 base pairs on each side
of the CpGs and considered 495 transcription factor
binding motifs defined by the HOMER software [25].
We identified enrichment for many transcription factors
involved in different cellular processes, including many
with known roles during erythropoiesis (Additional file 1:Table 1 Enrichment of transcription factor binding sites (TFBS
Motif name Consensus






















For these analyses, we used the HOMER software and analyzed TFBS located near C
The top 10 enriched motifs are shown here for each cell type; see Additional file 1:
using the Benjamini-Hochberg method. We calculated the fold enrichment by comp
adult erythroblasts. The consensus motif follows the IUPAC nomenclature when moTables S6-S7). In Table 1, we list the top transcription fac-
tors with binding motifs enriched near hypomethylated
CpGs.
In fetal erythroblasts, we observed enrichment for the
binding sites of SOX6 and GATA1, two key transcription
regulators of hematopoiesis [10,41,42]. GATA binding
motifs are also enriched at fetal-specific erythroid en-
hancers [20]. GATA1 and SOX6 are two transcription
factors important in fetal and adult erythroblasts, al-
though our results suggest that they may preferentially
bind hypomethylated sites in fetal erythroblasts [43].
The motif recognized by NFY was enriched near CpGs
hypomethylated in fetal erythroblasts: NFY binds the
HBG2 gene promoters to stimulate chromatin opening
[44]. In adult erythroblasts, we detected an enrichment
for the motif bound by NF-E2, a transcription factor im-
portant for erythroid maturation and HBB gene expres-
sion [45], as well as RUNX1, an important regulator of
mammalian hematopoiesis that acts upstream of NF-E2
[46]. IRF2 was recently established as a transcriptional
regulator of erythropoiesis that controls gene expression
through adult erythroid enhancers [20]. Binding sites for) near differentially methylated CpGs
P value q-value Fold enrichment
1.0 × 10−13 0 1.5
1.0 × 10−8 0 1.8
1.0 × 10−8 0 5.5
1.0 × 10−8 0 1.3
1.0 × 10−5 0.0001 2.4
1.0 × 10−5 0.0002 1.1
1.0 × 10−5 0.0002 1.4
1.0 × 10−5 0.0002 1.3
1.0 × 10−4 0.0004 1.4
1.0 × 10−4 0.0005 1.9
1.0 × 10−211 0 3.9
1.0 × 10−78 0 7.3
1.0 × 10−76 0 2.4
1.0 × 10−56 0 1.4
1.0 × 10−54 0 7.5
1.0 × 10−42 0 6.4
1.0 × 10−37 0 1.6
1.0 × 10−36 0 1.7
1.0 × 10−36 0 5.8
1.0 × 10−33 0 2.3
pGs (±200 base pairs) that are hypomethylated in fetal or adult erythroblasts.
Tables S6-S7 for the complete list of significant TFBS. We calculated q-values
aring the number of hypomethylated CpGs near a given TFBS in fetal and
re than one base is possible.
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are also enriched near hypomethylated CpGs in adult
erythroblasts. NRF2 is a transcriptional activator of the
antioxidant response and its pharmacological induction
in K562 cells results in increased HbF production [47].
The most enriched motif in adult erythroblasts belongs
to NF1, a family of transcription factors composed
of NFIA, NFIB, NFIC, and NFIX. Several differentially
methylated CpGs are located near NFIA, NIFC, and
NFIX (Additional file 2: Table S2), suggesting that the
expression of these transcription factors, as well as their
target genes, may be developmentally regulated by DNA
methylation during erythropoiesis. Over-expression of
NFIA in CD34+ cells leads to increased HBB gene ex-
pression [48].
DNA methylation and genetic variation control HBG2
expression
Treatment with DNA demethylating agents like 5-
azacytidine induces HbF production in primates and
humans [49,50]. The mechanism implies demethyla-
tion of the HBG2 promoter, directly or indirectly
through an effect on cellular stress, that results in an
increased synthesis of γ-globin chains [11,12]. However, it
is unknown whether changes in DNA methylation at loci
unlinked to the β-globin cluster on chromosome 11 can
also influence the production of HbF in humans. To ex-
plore this hypothesis, we tested if common DNA sequence
variants associated with HbF production in humans
are also associated with changes in DNA methylation
levels, that is if they are methylation quantitative trait
loci (meQTL). Indeed, recent findings suggest that
SNPs associated with complex diseases or traits may
exert their phenotypic effect by altering DNA methyla-
tion profiles [51,52].
We only analyzed associations between HbF-associated
SNPs and DNA methylation levels at the BCL11A (chr2:
60,678,302-60,781,633), HBS1L-MYB (chr6:135,281,517-
135,540,311), and β-globin (chr11:5,246,696- 5,527,882)
loci in adult erythroblasts. We did not include fetal eryth-
roblasts in this analysis because we reasoned that these
SNPs affect HbF production in adult erythroid cells. WeTable 2 Genetic and epigenetic control of HBG2/HBB expressi
Model rs3759074-A
BETA (SE)
Model 1: log(HBG2/HBB) ~ rs3759074 0.98 (0.42)
Model 2: log(HBG2/HBB) ~ CpG -
Model 3: log(HBG2/HBB) ~ rs3759074 + CpG 5.4 (1.6)
The A-allele at rs3759074 (chr11:5,257,778) is associated with increased fetal hemog
rs3759074-A is associated with increased expression of HBG2/HBB (Model 1). DNA m
correlated with HBG2/HBB expression (Model 2). Both genotypes at rs3759074 and
HBB expression levels (Model 3). For this analysis, we used adult erythroblasts from
the mean DNA methylation value at the tested CpG is 61 ± 8%. BETA: arbitrary genecomplemented the 450 k DNA methylation data with
measures of DNA methylation at CpGs in the HBG2 pro-
moter obtained using the targeted assay described above
(Additional file 1: Figure S3). We also measured by quanti-
tative PCR the expression of HBG2 and HBB in the same
adult cells. In our small sample size (N = 12), we did not
identify HbF-associated SNPs that are significantly associ-
ated with DNA methylation after accounting for the num-
ber of tests performed (Additional file 5: Table S8).
Focusing on the β-globin locus, we noted that increased
DNA methylation in the HBG2 promoter was associated
with a decreased HBG2/HBB gene expression ratio, as ex-
pected (Table 2). When we included in the prediction
model both DNA methylation levels at the HBG2 pro-
moter and genotypes at rs3759074, both terms were nom-
inally associated in the expected direction with the HBG2/
HBB expression ratio (Table 2). rs3759074 is in linkage
disequilibrium with the rs7482144-XmnI variant (r2 =
0.74) and falls within the BCL11A binding site identified
in a functional element important for HbF silencing [53].
In a mouse model, inactivation of BCL11A and treatment
with demethylating 5-aza-2’-deoxycytidine has a synergis-
tic effect on HbF production [21]. Together with these ob-
servations, our results suggest that changes in DNA
methylation at the HBG2 promoter act partly independ-
ently from genotypes at the β-globin locus to control HbF
production.
Conclusions
We generated comprehensive maps of DNA methylation
in human erythroblasts differentiated ex vivo from fetal
liver or bone marrow CD34+ progenitor cells. At single
base pair resolution, we identified 5,937 differentially
methylated CpGs that capture many of the transcrip-
tional differences - in terms of transcriptional enhancers
and transcription factor binding - between fetal- and
adult-stage cells. These analyses also revealed multiple
regions that could be of importance for HbF regulation,
as indicated by the enrichment of SNPs strongly associ-
ated with HbF levels within erythroid enhancers. Most
of the differentially methylated CpGs are hypermethy-
lated in fetal erythroblasts. We can explore further theseon in adult erythroblasts
CpG (chr11:5,276,172)
P BETA (SE) P
0.04 - -
- −6.1 (2.0) 0.01
0.008 −0.81 (0.30) 0.02
lobin production by genome-wide association studies. In adult erythroblasts,
ethylation at a CpG located in the HBG2 promoter (chr11:5,276,172) is inversely
DNA methylation at CpG (chr11:5,276,172) are independent predictors of HBG2/
12 donors. Within this dataset, the rs3759074-A allele frequency is 27% and
expression units; SE: Standard error.
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guishes fetal from adult erythroblasts during human
erythropoiesis.
Our study has some limitations. First, the technology
that we used to measure DNA methylation does not dis-
tinguish between methylation (5-methylcytosine, 5-mC)
and hydroxymethylation (5-hydroxymethylcytosine, 5-
hmC). This may be important to functionally explore as
5-mC and 5-hmC have different reported roles in the
context of gene regulation [54]. Second, some of the dif-
ferences observed in DNA methylation levels between
fetal and adult erythroblast may be due to slight differ-
ences in their growth kinetics. However, we expect this
number to be low since our cell morphology and gene
expression analyses indicate that these cells are largely
undistinguishable. Finally, our analysis of the effect of
genetic variation and DNA methylation on globin gene
expression is limited by our small sample size. Although
our results are consistent with the literature, validation
in independent samples is needed to confirm our addi-
tive model.
Clinically, one of the most important features of these
fetal and adult erythroid cells is their respective produc-
tion of HbF or HbA. In patients with sickle cell disease
or β-thalassemia, increasing HbF production improves
disease outcomes. In clinical trials, DNA demethylating
agents have shown modest efficacy in increasing HbF
production in patients [49,50]. On the other hand, work in
a sickle cell mouse model has shown that BCL11A-medi-
ated repression and 5-aza-2’-deoxycytidine treatment
synergistically control HbF production and improve
hematological parameters [21]. This is consistent with
our observation that a SNP within a BCL11A binding
site in a key regulatory element at the β-globin locus
and DNA methylation are independent predictors of
HBG2 expression in adult erythroblasts. Together, the
mouse and human erythroblast results suggest that a
combined strategy to inactivate BCL11A and promote
HBG2 demethylation may provide the robust induction of
HbF production necessary to treat β-hemoglobinopathy
patients.
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